About Alfasigma
Alfasigma is a company based in Bologna (Italy) founded in 2015. Alfasigma has completed 4 acquisitions, including Intercept Pharmaceuticals, Jyseleca and Pamlab.
- Headquarter Bologna, Italy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alfasigma India Private Limited
- Date of Incorporation 06 Aug, 2008
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$90.85 K (USD)-33.82as on Dec 31, 2019
-
Net Profit
-$80.25 K (USD)-504.4as on Dec 31, 2019
-
EBITDA
-$77.22 K (USD)-403.78as on Dec 31, 2019
-
Latest Funding Round
$176.07 M (USD), Debt – Conventional
Jul 08, 2025
-
Investors
BPER Banca
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Intercept Pharmaceuticals
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Alfasigma
Investors in Alfasigma
Alfasigma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BPER Banca and European Investment Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Regional banking and investment services are provided to various clients.
|
Locked | Locked | Locked |
Investor details for Alfasigma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alfasigma
Alfasigma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Intercept Pharmaceuticals, Jyseleca and Pamlab.
Investment portfolio details for Alfasigma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of therapeutics to treat progressive non-viral liver diseases
|
Locked | Locked | 2002 | Locked | |
|
Pharmaceutical finished products such as tablets and capsules are manufactured.
|
Locked | Locked | 1968 | Locked | |
|
Pharmaceutical company providing prescription medical food
|
Locked | Locked | 1957 | Locked |
Complete acquisition details for Alfasigma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alfasigma
Detailed financials for Alfasigma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alfasigma Comparisons
Peer comparison for Alfasigma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alfasigma
Detailed competitors of Alfasigma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alfasigma
Complete news archive for Alfasigma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alfasigma
Alfasigma was founded in 2015 and raised its 1st funding round 10 years after it was founded.
Alfasigma is headquartered in Bologna, Italy. It is registered at Bologna, Emilia-romagna, Italy.
Bryan Downey is the current CEO of Alfasigma.
Annual revenue of Alfasigma is $90.85K as on Dec 31, 2019.
Alfasigma was established in 2015 and is based in Bologna, Italy, within the pharmaceutical sector. Finished generic formulations, including tablets, capsules, syrups, and injectables, are produced by the company. Operations focus on key products such as rifaximin, carnitine, sulodexide, and parnaparin, supporting generic drug distribution across various markets.
Alfasigma has made 4 acquisitions, including Intercept Pharmaceuticals, Jyseleca, and Pamlab.
Alfasigma has 2 investors. Key investors include BPER Banca, and European Investment Bank.